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Abstract 
Although survival rates for lymphoproliferative disorders are steadily increasing both in the US and in Europe, there 
is need for optimizing front-line therapies and developing more effective salvage strategies. Recent advances in 
molecular genetics have highlighted the biological diversity of lymphoproliferative disorders. In particular, integrative 
approaches including whole genome sequencing, whole exome sequencing, and transcriptome or RNA sequencing 
have been instrumental to the identification of molecular targets for treatment. Herein, we will discuss how genomic, 
epigenomic and proteomic approaches in lymphoproliferative disorders have supported the discovery of molecular 
lesions and their therapeutic targeting in the clinic.
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Background
The growing medical needs in terms of cost reduction, 
care of elderly patients, increasing quality requirements 
and management, pose new hurdles to health profession-
als. Systems medicine (SM) is a fascinating approach to 
provide answers to these challenges. SM can be defined 
as an interdisciplinary, pro-active approach to the treat-
ment of diseases that follows the P4 paradigm: predic-
tive, preventive, personalized and participatory [1, 2]. SM 
takes advantage of a systems biology approach, whereby 
biological, clinical, environmental and lifestyle informa-
tion is integrated through iterative statistical analyses, 
computational modelling and experimental validation 
[1].
A variety of hematological malignancies have been 
characterised, at least partially, using whole genome 
sequencing (WGS), whole exome sequencing (WES), 
transcriptome or RNA sequencing, including acute and 
chronic leukemias and lymphomas. The data derived 
from these efforts have provided pathogenetic insights, 
as well as diagnostic and therapeutic information, and 
they have identified molecular lesions amenable to tar-
geted interventions. Next generation sequencing (NGS) 
or massively parallel sequencing refers to a technology 
which does not depend on traditional electrophoresis-
based Sanger sequencing (i.e., the first generation) [3]. 
NGS platforms can be broadly divided into second gen-
eration (i.e., methods requiring template amplification 
before sequencing) and third generation (i.e., methods 
that sequence templates directly without amplification). 
Sophisticated computational tools are required to map 
and assemble the massive amount of data generated from 
a single NGS reaction.
The management of chronic lymphoproliferative dis-
orders is a considerable burden on public health [4]. 
Non-Hodgkin lymphomas (NHL) are most frequently 
diagnosed in patients aged 65–74 (median age at diag-
nosis being 66 years) and account for 4.3 % of new can-
cer cases in the US [5]. NHLs are, therefore, the seventh 
most common type of cancer diagnosed in the US. The 
population age is increasing in Western countries, imply-
ing that the impact of healthcare costs necessary to cure 
these malignancies will be increasing as well. Death rates 
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have been declining by 2.6 % on average each year dur-
ing 2002–2011. The 5-year survival rate for NHLs cur-
rently approaches 70  % [5]. Specifically, survival rates 
for follicular lymphoma (FL) increased from 59 to 74 %, 
and those for chronic lymphocytic leukemia (CLL)/small 
lymphocytic lymphoma (SLL) from 66 to 69 % [4]. Simi-
larly, EUROCARE and HAEMACARE data on 560,444 
patients with haematological malignancies show an 
increased survival for most disease types in European 
countries, with the largest increase being for diffuse large 
B-cell lymphoma (DLBCL) and FL. However, persistent 
differences in survival across Europe point to the need 
for minimizing variations in the quality of care and avail-
ability of new treatments [4].
NHLs comprise over 60 disease subtypes and include 
both aggressive and indolent lymphoma subgroups. 
Approximately 95 % of lymphomas in the Western world 
are of B-cell origin. This overrepresentation largely origi-
nates from misrepair of DNA lesions introduced by 
activation-induced cytidine deaminase (AID), a B cell-
specific cytidine deaminase that initiates class switch 
recombination and somatic hypermutation (SHM) of 
immunoglobulin (Ig) genes [6]. The three most common 
subtypes of NHL are represented by DLBCL, FL and 
CLL/SLL [7]. This article will discuss how genomic, epi-
genomic and proteomic approaches have supported the 
discovery of molecular targets in well-established lym-
phoid malignancies [8]. The main studies covered in this 
paper have been summarised in Table 1.
Use of high‑throughput approaches to identify molecular 
targets in DLBCL
DLBCL is an aggressive type of NHL, accounting for 
approximately 30 % of adult NHLs diagnosed in Western 
countries [9]. A breakthrough in the treatment of DLBCL 
was represented by the use of the monoclonal antibody 
rituximab in addition to standard CHOP chemotherapy 
(R-CHOP), which led to shortening of time to disease 
progression and to dramatic improvements in overall 
survival (OS) [10, 11].
The cell of origin is an important prognosticator in 
DLBCLs. Gene expression profiling (GEP) has allowed 
the identification of three molecular subtypes of 
DLBCLs, i.e., germinal center B-cell-like DLBCL (GCB), 
activated B-cell-like (ABC) DLBCLs, and primary medi-
astinal B-cell lymphoma (PMBL) [12]. High-resolution, 
genome-wide copy number analysis coupled with GEP 
has indicated that GCB, ABC and PMBL are different 
diseases that use distinct oncogenic pathways and have a 
different prognosis [13].
GEP studies contributed further to the molecular and 
prognostic classification of DLBCLs through the iden-
tification of “stromal-1” and “stromal-2” signatures in a 
training group as well as a validation cohort of patients 
[14]. Molecular signatures were related to the micro-
environment and predicted either a favorable outcome 
(stromal-1) by reflecting extracellular matrix deposition 
and macrophage infiltration of the tumor or a less favora-
ble outcome (stromal-2) as a result of tumor blood ves-
sel density. The stromal-1 and stromal-2 signature genes 
were more highly expressed in the nonmalignant CD19− 
fraction compared with CD19+ lymphoma cells. These 
signatures were found both in GCB-DLBCL and in ABC-
DLBCL, reflecting biological attributes of both subtypes 
of DLBCL [15].
At genetic level, massive parallel sequencing tech-
niques revealed a remarkable complexity of DLBCLs 
represented by translocations, gene amplifications, sin-
gle nucleotide variants but also copy number variations. 
Interestingly, recent genomic studies unveiled lesions 
affecting histone/chromatin modification enzymes, such 
as CREBBP, EP300, MLL and EZH2 [16–18]. A further 
layer of complexity is represented by methylation pro-
files analyzed at the genome level. Methylation variability 
profiles (MVP) and methylation variability scores (MVS) 
have been recently introduced as novel methods to meas-
ure methylation disruption in lymphomas [19]. These 
parameters describe the deviation of the methylation pat-
terns of DLBCLs from normal GCB cells (NGCB). They 
have been recently introduced and define six separate 
clusters in a cohort of 140 DLBCL analyzed. The mag-
nitude of the methylation deviation from NGCB associ-
ates with survival of patients receiving R-CHOP, insofar 
patients with a larger magnitude of methylation changes 
display poorer survival compared with patients with 
smaller magnitude of methylation changes [19].
MYC oncogene rearrangements impart an unfavora-
ble prognosis on lymphomas [20, 21]. Furthermore, the 
prognostic impact of MYC dysregulation is strongly 
influenced by concomitant BCL2 aberrations. The con-
current translocation of MYC and BCL2 occurs in 
approximately 5  % of DLBCLs and defines “double-hit” 
lymphomas that are treatment-refractory, with a median 
survival of ~8 months [22, 23]. Dual expression of these 
proteins is more common in ABC-DLBCLs and may 
explain its poorer survival [24]. This evidence points to 
the importance of assessing DLBCL patients for concur-
rent deregulation of MYC and BCL2 at time of diagnosis, 
both at the level of translocations and protein overex-
pression [15].
Our knowledge of the biological heterogeneity of 
DLBCLs has prompted the development of novel tar-
geted therapies, that have the potential for greater tumor 
specificity and lower generalized toxicity. An exam-
ple is represented by agents that target B-cell recep-
tor (BCR) signaling in DLBCLs. For instance, members 
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of the NF-κB pathway are constitutively activated in 
ABC-DLBCLs [25, 26]. The activation of NF-κB in ABC-
DLBCLs consists of an amplification of upstream onco-
genic signalling, since it creates multiple feed-forward 
and feed-back signaling loops through transcriptional 
activation of target genes required for survival [27]. ABC-
DLBCLs with an activated JAK/STAT signaling have a 
higher NF-κB target gene expression [12]. Interference 
with NF-κB activity induces cell cycle arrest and trig-
gers apoptosis. In this respect, small-molecule inhibitors 
blocking the degradation of the NF-κB inhibitor IκBα 
or the activation of IKK are reportedly toxic for ABC-
DLBCLs [28, 29].
The transcription factor IRF4 is, among others, a key 
player insofar it supports the survival of ABC-DLBCLs 
and, together with BAFF, is required downstream of BCR 
signaling to promote transcriptional programs during 
germinal centre formation [30].
B lymphocytes express a surface membrane B-cell 
receptor (BCR), which comprises a canonical immu-
noglobulin (heavy and light chains) coupled to a heter-
odimer CD79a/CD79b (Igα/Igβ), which is required for 
plasma membrane expression, intracellular trafficking 
and signal transduction. A distinctive characteristic of 
the BCR is that ABC-DLBCLs often express IgM-BCR on 
their surface, whereas GCB-DLBCLs typically show IgG-
BCR switching [31]. There are inactivating events that 
specifically occur in the productive (in-frame) IgH allele 
in ABC-DLBCLs, whereas the non-productive (out of 
frame) IgH alleles switch to a different isotype [32]. This 
leads to a selective pressure on ABC-DLBCLs to main-
tain an IgM isotype in the IgM-BCR. The IgM- and IgG-
BCR induce qualitatively different signaling cascades and, 
ultimately, transcriptional programs.
The CARD11 cytoplasmic scaffolding protein is a bona 
fide oncogenic protein that, when mutated, contributes 
to constitutive activation of NF-κB and enhanced NF-κB 
activity upon antigen-receptor stimulation [33]. The 
CARD11 protein is part of the so-called “CBM-complex” 
that is critical to the activation of the classical NF-κB 
pathway downstream of B- and T-cell antigen receptors 
[34]. The CBM complex mediates signaling from BCR to 
NF-κB. The Bruton tyrosine-kinase (Btk) is critical for 
the survival of ABC cell lines with wild-type CARD11, 
but not GCB lines or ABC lines with mutated CARD11 
[35]. Ibrutinib is a novel inhibitor of Btk that has signifi-
cant antitumor activity towards relapsed and refractory 
CLL, mantle-cell lymphoma and is currently in clinical 
trials for DLBCL [36, 37]. It is an irreversible inhibitor 
that forms a covalent bond with cysteine 481 adjacent 
to the active site of Btk, and has a high degree of speci-
ficity and potency. The better clinical response of ABC-
DLBCLs to ibrutinib compared with GCB-DLBCLs 
supports the hypothesis that ABC-DLBCLs, but not 
GCB-DLBCLs, rely on the chronic activation of BCR 
signalling [38].
Another mechanism leading to the BCR-independ-
ent activation of the NF-κB pathway is mediated by the 
adapter MyD88, which is an inducer of NF-κB activity 
upon Toll-like receptor (TLR) stimulation of immune 
cells [39]. Mutant MYD88 isoforms, as well as ectopic 
expression of MyD88 mutants in heterologous cells, are 
potent activators of NF-κB [39].
Bortezomib is an NF-κB targeting drug that blocks the 
degradation of IκBα and has shown to benefit patients 
with relapsed ABC-DLBCLs, when combined with dose-
adjusted EPOCH-R chemotherapy [40].
Use of high‑throughput approaches to identify molecular 
targets in FL
FLs have features of germinal center B cells and are cur-
rently considered incurable diseases when treated with 
conventional chemotherapy or immunotherapy. Under-
standing the evolution dynamics of FL clones is crucial to 
monitor disease progression and to effectively target FLs. 
Whole-genome and transcriptome sequencing of BCL2 
translocation-positive FLs in comparison with IG-MYC 
translocation-positive Burkitt lymphoma and normal 
germinal center B-cell samples showed differential meth-
ylation of intragenic regions that strongly correlated with 
expression of genes active in germinal center dark-zone 
and light-zone B cells [41]. These data point to a close 
connection between somatic mutation, DNA methyla-
tion and transcriptional control in B-cell pathways in FLs 
and other germinal center B-cell lymphomas.
Genetic profiling of serial FL biopsies suggests that FLs 
may derive by divergent evolution from a common ances-
tor cell. The pattern of somatic hypermutation of the Ig 
gene provides useful information about B-cell clonal 
evolution within the germinal center and also allows to 
discriminate B cells that entered the germinal center and 
display features of ancestor cells from B cells that con-
tinue to re-circulate across different lymphoid organs. 
The pattern of somatic hypermutation of the heavy 
chain of the immunoglobulin gene (IgH-VH) was exam-
ined using the GS-FLX Titanium sequencing platform 
in flow-sorted B cells of various differentiation stage, 
obtained from lymph node biopsies of FL patients with 
various patterns of evolution [42]. The authors reported 
a high level of clonality, with hundreds of distinct tumor 
subclones being detected in different cell subpopula-
tions from the same patient sample. By using a lineage 
trees analysis, the oligoclonal FL population in all cases 
was shown to reside in an intermediate stage of matura-
tion that maintains the capacity to undergo SHM, but is 
unable to further differentiate.
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Intraclonal heterogeneity in FLs is supported by stud-
ies of SHM caused by AID in IGH. Aberrant SHM is 
defined as AID activity outside of the IG loci and mainly 
targets noncoding regions, inducing “passenger” muta-
tions, but also having the potential to generate rare 
“driver” mutations. Ultradeep sequencing (>20,000-
fold coverage) has been used to define the quantitative 
relationship between SHM and aberrant SHM on IGH 
(~1650 nt) and nine other noncoding regions potentially 
targeted by AID [43]. Single-nucleotide variants (SNVs) 
could be detected in 12/12 FL specimens. The aberrant 
SHM SNVs were associated with AID motifs. The rela-
tive number of SNVs with variable allele frequency <5 % 
varied with clinical grade, suggesting that tumor hetero-
geneity based on aberrant SHM may serve as a clinically 
relevant parameter.
Another study of WGS or WES followed by deep 
sequencing of 28 genes led to the identification of recur-
rent FL mutations in linker histone, JAK-STAT signal-
ing, NF-κB signaling and B-cell developmental genes 
[44]. Longitudinal analyses allowed the detection of early 
driver mutations in chromatin regulator genes, whereas 
mutations in EBF1 and regulators of NF-κB signaling 
were gained at transformation. The remarkable intratu-
moral diversity within FLs is supported by studies show-
ing a clonal hierarchy when comparing diagnosis and 
relapse tumor pairs, resolved using immunoglobulin 
somatic mutations and IGH-BCL2 translocations [45]. 
Using this approach, early versus late genetic events were 
clearly distinguished during lymphomagenesis. More 
specifically, IGH-BCL2 translocations and CREBBP 
mutations may be early events, whereas MLL2 and 
TNFRSF14 mutations may represent late events during 
FL evolution.
Use of high‑throughput approaches to identify molecular 
targets in CLL
CLL is a common B-cell malignancy characterized by a 
highly variable clinical course. A “watch-and-wait” thera-
peutic approach has long been advocated for patients 
without symptomatic disease, with frontline chemother-
apy being a conventional choice for patients requiring 
treatment. More recently, new drugs have been approved 
for the treatment of patients with CLL, including novel 
CD20-targeting antibody obinutuzumab, PI3-kinase 
inhibitor idelalisib, and irreversible inhibitor of Bru-
ton tyrosine kinase ibrutinib [46]. Our understanding of 
CLL genetics has been furthered by large-scale studies of 
massively parallel sequencing, which have unveiled the 
genetic and epigenetic heterogeneity among patients, and 
within individual patient samples. The most recurrent 
lesions identified, i.e., deletions of chromosome 13q (55 % 
of cases), 17p (7  %), and 11q (6–18  %); and trisomy 12 
(12–16 %), reportedly contain putative CLL drivers, such 
as ATM and BIRC3 in 11q, TP53 in 17p, and miR-15a/16 
encoded in an intron of DLEU2 in 13q [46]. Other clini-
cally relevant gene mutations in CLL involve NOTCH1, 
SF3B1, and MYD88 [47]. It has been shown that addition 
of integrated mutational and cytogenetic information can 
improve prediction of OS in patients with CLL compared 
with cytogenetics alone [48].
The SHM status of the clonotypic rearranged immuno-
globulin (Ig) heavy chain variable region (IGHV) gene is 
strongly associated with patient outcome [49]. Recently, 
the complete haplotype DNA sequence of the human 
Ig heavy-chain variable, diversity and joining genes was 
described. The authors also identified four large germline 
copy-number variants (CNVs) and eight CNV-containing 
haplotypes in addition to previously unmapped IGHV 
genes [50]. The international ImMunoGeneTics informa-
tion system (IMGT®) has been enriched with these novel 
IGHV genes and alleles and the new sequences have been 
incorporated into a database and into reference directo-
ries [51]. The tool used to analyze the rearranged IGH 
sequences was the IMGT/highV-QUEST portal for NGS 
Ig and T-cell receptor sequences [52]. This is a high-
throughput version of the IMGT/V-QUEST that meets 
the needs of deep-sequencing data analysis coming from 
NGS platforms, allowing for the simultaneous analysis of 
thousands of Ig and T-cell receptor sequences in a single 
run.
Genome-wide chromatin accessibility maps for CLL 
have been measured by the assay for transposase-acces-
sible chromatin using sequencing (ATAC-seq) [53]. 
Significant differences in chromatin accessibility were 
shown for regions in the vicinity of genes that were iden-
tified as differentially expressed between IGHV-mutated 
and IGHV-unmutated CLL, allowing partial separation 
of two disease subtypes. IGHV mutation status could be 
predicted by the chromatin profiles and gene regulatory 
networks inferred for IGHV-mutated vs. IGHV-unmu-
tated samples. This chromatic profiling assays should be 
straightforward to use in a clinical sequencing labora-
tory, allowing deeper insights into chromatic regulation 
in CLL as well as detection of biomarkers for stratified 
cancer therapy.
The presence of uracil into the DNA sequences was, 
until recently, considered the result of a misincorpora-
tion of dUMP during DNA replication and of sponta-
neous deamination of DNA cytosine. AID belongs to 
the family of APOBEC cytosine deaminases and repre-
sents a third source of uracil within the DNA sequence 
[54]. The DNA cytosine deamination by APOBEC-
family enzymes is a natural event in both adaptive and 
innate immune responses through targeted deamina-
tion of Ig genes by AID and deamination of viral DNA 
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by APOBEC enzymes, respectively [55]. Interestingly, 
recent data demonstrate that B-cell lymphoma cell lines 
contain several-fold increased levels of genomic uracil 
compared to normal human lymphocytes and non-lym-
phoma cell lines. Moreover, genomic uracil content cor-
related with AID protein expression and not with other 
APOBEC enzymes [54]. Analysis of exome sequencing 
data from lymphomas and CLL unravelled that these 
lymphoid malignancies may carry a distinct AID-hotspot 
mutational signature in kataegis regions, i.e., localized 
hypermutations in small regions that are also associated 
with genomic rearrangements [56]. Thus, AID-induced 
genomic uracil formation may be implicated in the devel-
opment of localized hypermutation in B-cell malignan-
cies [54].
A significant application of NGS allowed the assess-
ment of the subclonal development based on mutations 
in the IGHV-D-J signature sequence in the dominant 
CLL clone [57]. This approach consistently evidenced, 
the occurrence of APOBEC and AID targeted mutations.
WGS studies in low-risk CLL patients with chromo-
some 13q deletion or normal cytogenetics showed that 
mutations in known CLL drivers are observed in only 
33 % of this patient cohort, and are associated with nor-
mal cytogenetics and unmutated IGHV [58]. The IGLL5 
gene, which is homologous to IGLL1 (lambda5) and is 
critical for B-cell development, was the most commonly 
mutated gene and the mutational pattern suggested the 
potential involvement of AID activity. Three mutational 
signatures were identified, including two distinct AID 
processes (canonical AID and noncanonical-AID) that 
represent a greater fraction of mutational activity in 
mutated IGHV cases, and an ageing-related signature. 
The clonal or subclonal nature of a mutation was used to 
infer the time of occurrence of that mutation in relation 
to initial malignant transformation, the prediction being 
that clonal mutations occur earlier. Using this approach, 
noncanonical-AID-associated mutations were shown to 
occur in tumour evolution, whereas the ageing signature 
activity was enriched in patients with late-onset disease 
and enriched in subclonal mutations, which occur later 
[58].
The efficacy of WES approach in the discovery of driver 
mutations in CLL is further confirmed by the finding 
that 18 novel driver mutations were unveiled only with 
the use of this technique. These novel driver mutations 
hit histone proteins (HIST1H1D; HIST1HIC) involved in 
resistance to lenalidomide in multiple myeloma (IKZF3), 
nuclear RNA export factor 1 (NXF1) and proteins also 
mutated in acute myeloid leukemia and multiple mye-
loma (ASXL1; TRAF3) [59]. RNA sequencing (RNAseq) 
approaches were next used to validate the novel driver 
mutations emerged from WES analysis.
Proteomic analysis also represents a useful approach 
to the molecular classification of CLL. The mutational 
status of the IGHV genes defines two clinically distinct 
disease forms, known as mutated CLL (M-CLL) and 
unmutated CLL (UM-CLL). Patients with M-CLL usu-
ally have a favorable outcome, whereas patients with 
UM-CLL develop progressive disease and have shorter 
survival [60]. Quantitative proteomic analysis through 
the use of the iTRAQ-MS platform allowed the identifi-
cation of two subsets of CLL clearly reflecting the IGHV 
mutational status. Specifically, 274 proteins were found 
to be differentially expressed when comparing UM-CLL 
and M-CLL samples. Proteomic analysis also allowed the 
establishment of a novel correlation between lymphad-
enopathy and UM-CLL, leading to the hypothesis that 
retention of malignant B cells in lymph nodes of UM-
CLLs may underpin the development of lymphadenopa-
thy [61].
Double IGHV gene rearrangements have been shown 
to correlate with patient prognosis in CLL [62]. Although 
differences in survival were not detected between 
patients with single or double IGHV chain rearrange-
ments, the presence of at least one mutated IGHV gene 
conferred a better prognosis to patients with double 
IGVH rearrangements, suggesting that patients with 
double IGHV rearrangements with at least one mutated 
IGHV should be offered the same treatment intensity as 
those with a mutated rearrangement [62].
CLL is sensitive to immune system attack and is ame-
nable to immune interventions, including the adoptive 
transfer of genetically modified T cells [63]. Rajasagi and 
co-workers [64] used WES and WGS to identify neoan-
tigens presented by patient-specific HLA alleles. Neo-
antigens are generated from peptides encoded by gene 
alterations that are exclusively present in the tumor but 
not in normal tissues, and qualify as attractive targets for 
anti-tumor vaccination strategies. Using samples from 
91 patients with CLL, 22 mutated binding peptides were 
predicted. In addition, HLA binding was experimentally 
confirmed for 55 % of such peptides. Neoantigen-specific 
T-cell responses were also monitored in CLL patients 
in continuous complete remission for >4  years after 
reduced-intensity hematopoietic stem cell transplanta-
tion (HSCT). In the first patient, 25 missense mutations 
were identified by WES. Patient T cells were expanded 
using antigen-presenting cells and peptide pools from the 
candidate neoantigen. Based on IFN-γ release, reactivity 
against the mutated peptides, but not against irrelevant 
peptides, was readily identified. In the second patient, 26 
missense mutations were discovered and polyfunctional, 
highly avid memory T-cell responses were measured 
in  vitro. Using mutant-specific tetramers, neoantigen-
specific T cells could be detected and tracked in  vivo 
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coinciding with the achievement of molecular remission 
after HSCT.
Chimeric antigen receptor (CAR)-modified T cells 
have recently generated enthusiasm as an immunother-
apy approach for lymphoproliferative malignancies [65]. 
Whereas CAR T cells typically target highly expressed 
antigens, low antigen-expressing tumours may develop 
resistance to CAR T-cell therapy. Interestingly, epigenetic 
modulators were shown to increase the expression levels 
of tumour-associated antigens, thus rendering tumour 
targets highly susceptible to immune system attack. The 
hypomethylating agent 5-aza-2′-deoxycytidine (DAC) 
induces NY-ESO-1, a cancer-testis antigen, in multiple 
myeloma and breast cancer cells in a time- and dose-
dependent manner, with maximal effects being shown 
after incubation with 10  μM DAC for 72  h [66]. Single 
NY-ESO-1 peptides presented in the context of HLA-
A*0201 molecules were increased by 100 and 50  % on 
MCF7 and U266 cells, respectively. This was reflected 
into an increased lysis of tumour targets by HLA-
A*0201/NY-ESO-1157–165 peptide-specific CAR CD8+ T 
cells [66]. A similar approach has been used to increase 
the intensity of other tumour-associated antigens, i.e., 
mucin-1 (MUC-1) and prostate stem cell antigen (PSCA) 
[67]. In mice, complete eradication of pancreatic tumours 
is not achieved irrespective of the simultaneous chal-
lenge of pancreatic tumour cells (CAPAN1) with CAR 
T cells targeting both MUC-1 and PSCA [67]. However, 
CAPAN1 cells expressing low levels of MUC-1 as a result 
of immune escape mechanisms can be re-sensitised to 
the killing effect of CAR T cells after 4-day treatment 
with decitabine. Overall, these studies suggest that hypo-
ethylating agents could be of benefit in the context of 
CAR T-cell immunotherapy trials that target a variety of 
tumour types.
Mutational burden and immune checkpoint inhibitors 
in lymphoid malignancies
The use of immune checkpoint inhibitors for the treat-
ment of haematological malignancies has raised consid-
erable interest [68]. These agents do not target the cancer 
cells directly but rather enhance the cytotoxic activity of 
host T cells by blocking inhibitory signals from tumour 
cells. Cancer types harbouring more somatic mutations, 
i.e., lung cancer and melanoma, are expected to more 
frequently express neo-antigens that are recognized 
by autologous T cells, and should be more susceptible 
to checkpoint inhibitors [69]. It is presently unknown 
whether lymphoid malignancies may be less amenable to 
treatment with checkpoint inhibitors than solid tumours, 
based on the lower number of somatic mutations per 
megabase of coding DNA. Differences in response 
have been demonstrated across various haematological 
malignancies [70]. For instance, checkpoint inhibition is 
undoubtedly a promising strategy in classical Hodgkin 
lymphoma (HL). Recent analyses integrating high-res-
olution copy-number data and transcriptional profiles 
identified PD-L1 and PD-L2 as key targets of 9p24.1 
amplification, which is a recurrent genetic abnormality in 
HL and may lead to overexpression of the PD-1 ligands 
on the Reed-Sternberg cell surface [71]. A recent study 
enrolled 23 patients with multiply relapsed or refrac-
tory HL, who received nivolumab (at a dose of 3 mg per 
kilogram of body weight) every 2 weeks until they had a 
complete response, tumor progression, or excessive toxic 
effects [72]. An objective response was reported in 87 % 
of patients, including 17  % with a complete response 
and 70  % with a partial response. The remaining 13  % 
of patients had stable disease. Analyses of pretreat-
ment tumor specimens from a subgroup of ten patients 
showed copy number gains in PD-L1 and PD-L2 as well 
as increased expression of these ligands [72].
Immune checkpoint blockade has been shown to exert 
therapeutic activity in at least FL and DLBCL. A phase 
2 MD Anderson Cancer Centre trial to investigate the 
activity of pidilizumab, a humanised anti-PD1 monoclo-
nal antibody, with rituximab in 32 adult patients with 
relapsed FL showed objective responses in 66 % of evalu-
able patients, including complete responses in 52 % and 
partial responses in 14 % of patients [73].
A phase Ib study in relapsed or refractory B-cell lym-
phoma, T-cell lymphoma, and multiple myeloma has 
shown the efficacy of the anti-PD-1 monoclonal antibody 
nivolumab, with 40, 36, 15 and 40 % objective response 
rates among patients with FL, DLBCL, mycosis fun-
goides, and peripheral T-cell lymphoma, respectively 
[74]. By contrast, tumour regression responses were not 
observed among patients with multiple myeloma, with 
the exception of one complete remission occurring after 
local radiation therapy. The reason for the lack of objec-
tive responses in MM, compared with other tumors, 
remain speculative and may be related to immunosup-
pressive circuits within the myeloma tumour microen-
vironment [75]. Also, differences in the composition and 
quality of the immune infiltrate may account for differ-
ences in clinical responses across the wide spectrum of 
lymphoid malignancies.
The emerging role of epigenomics
Epigenetics and epigenomics focus on the study of chro-
matin, i.e., the complex of DNA, proteins, and non-cod-
ing RNAs (ncRNAs) that form the structural matrix of a 
chromosome. The spectrum of epigenetic modifications 
that regulate chromatin encompasses DNA methyla-
tion, histone modifications, and ncRNAs [76]. Epigenetic 
changes are modifications that do not alter the genomic 
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nucleotide sequence but influence gene regulation and 
expression [77]. Changes involving gene expression 
control through epigenetic modifications are increas-
ingly recognized as major mechanisms involved in the 
development of a variety of diseases, including cancer. 
These modifications can be reverted through pharma-
cologic treatment (such as small molecules, antibodies 
and inhibitors) and, therefore, identification of groups 
of patients with specific epigenomic alterations may lead 
to therapeutic benefits [78]. Furthermore, seven among 
the top ten leading causes of death listed by the World 
Health Organization in 2010 were diseases with an epi-
genetic and epigenomic component, underlying the need 
for boosting research efforts in this field [79]. The most 
updated molecular techniques and related bioinformatics 
platforms used for the epigenomic profiling of patients 
are shown schematically in Fig. 1.
DNA methylation is a key epigenetic mechanism used 
by higher eukaryotes for gene expression regulation, 
imprinting and silencing of germline specific genes and 
repetitive elements [80]. Methylation patterns are sta-
bly maintained through somatic cell division and can be 
inherited across generations. Since perturbed methyla-
tion patterns are linked to pathologic conditions such as 
imprinting disorders and cancer, understanding how 
these patterns are established and maintained is of great 
importance [81].
It is increasingly recognized that the epigenomic pro-
filing of patients represents a useful tool in the path 
towards personalized medicine [77]. A growing body of 
evidence suggests that different molecular approaches 
should be integrated in order to build a realistic profile 
of the disease status of patients. Among these advanced 
technologies, epigenomic profiling is becoming a fun-
damental tool to explore gene expression regulation. 
Dysfunctional methylation patterns, for instance, may 
become the signature of a specific cancer whereas over-
expression of specific deacetylases can be univocally 
associated with distinct malignancies. As epigenetic 
therapies advance towards the clinic, genomic/epig-
enomic tools will support the identification of patients 
who will most likely benefit from hypomethylating 
drugs.
Very informative in this context is the National Insti-
tutes of Health (NIH) Epigenomics Roadmap, a bio-
informatics platform prompted by the NIH Roadmap 
Epigenomics Mapping Consortium [82]. This consortium 
developed a panel of resources based on NGS technolo-
gies in order to map DNA methylation, histone modifica-
tions, chromatin accessibility and small RNA transcripts 
in stem cells and primary ex  vivo tissues that represent 
normal counterparts of tissues frequently involved in 
human disease. The NIH Epigenomics roadmap pro-
vides not only updated databases with the epigenomes 
of human cell types, tissues or whole organs but also 
protocols and reference guidelines for the scientific 
community.
Aberrant DNA methylation pattern is considered a 
hallmark of cancer, and may contribute to lymphoma 
phenotypes and chemoresistance of cancer cells. Decit-
abine is a nucleoside analogue that, after being incor-
porated into DNA, inhibits DNA methyltransferases 
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(DNMTs) and acts as an hypomethylating agent. Decit-
abine has been approved for the treatment of myelo-
dysplastic syndromes. A recent phase I study aimed 
at targeting aberrant DNA methylation in relapsed/
refractory CLL and NHL by administering 1–3 cycles of 
decitabine [83]. Dose-limiting toxicity, consisting of mye-
losuppression and infectious complications, was docu-
mented in 2 of 4 patients with CLL and in 2 of 2 patients 
with NHL given decitabine at 15  mg/m2. Six patients 
received 10 mg/m2 decitabine for 10 days without DLTs 
and with no change in global DNA methylation or re-
expression of methylated genes. When a 5-day decitabine 
schedule was evaluated, DLTs were observed in 2 of 6 
CLL and 2 of 2 NHL patients, suggesting that dose esca-
lation to levels associated with methylation changes may 
be difficult to achieve in patients.
The relevance of targeting DNMTs has also been 
explored in DLBCLs where chemoresistance is asso-
ciated with aberrant DNA methylation programming 
[84]. Prolonged exposure to low-dose DNMT inhibi-
tors reprogrammed chemoresistant cells and restored 
sensitivity to doxorubicin. A group of nine genes was 
found to be recurrently hypermethylated in chemoresist-
ant DLBCL with SMAD1, a TGF-β pathway transducer, 
being an important contributor. A subsequent phase I 
study evaluated the impact of azacitidine priming for 
5 days, followed by R-CHOP chemo-immunotherapy, in 
12 patients with newly diagnosed DLBCL. Eleven of 12 
patients achieved a complete response and ten remained 
in remission at median follow-up of 13 months. Patient 
biopsies obtained before and after treatment confirmed 
an increase of SMAD1 mRNA and a decrease in SMAD1 
methylation, as well as a remarkable increase in the frac-
tion of dead cells in the post-azacitidine samples. This 
study suggests that DNMT inhibitors may play a role 
in priming high-risk DLBCLs before administration of 
chemotherapy.
Decitabine has also been used in combination with 
vorinostat, a small molecule that binds to and directly 
inhibits histone deacetylase, and is approved for the 
treatment of cutaneous T-cell lymphoma. This phase I 
study enrolled 43 patients with advanced solid tumors 
and NHL [85]. Both sequential and concurrent schedules 
were evaluated in nine different dose levels (6 sequential 
and 3 concurrent). The sequential schedule of decitabine 
10 mg/m2/day on days 1–5 and vorinostat 200 mg twice 
a day on days 6–12 qualified as the recommended phase 
II dose in this study. Disease stabilization for four cycles 
or more was observed in approximately 30 % of evaluable 
patients, suggesting that the combination of decitabine 
with vorinostat is tolerable and shows activity in different 
tumor types.
Therapeutic implications of genetic findings
Recent insights into the molecular complexity of lym-
phoproliferative disorders are expected to herald break-
throughs in disease classification, prognostication and 
treatment. In addition to the major molecular designa-
tions of GCB and ABC subtypes, NGS technologies have 
unravelled the remarkable heterogeneity and complexity 
of DLBCL and identified molecular targets that may be 
selectively exploited for therapeutic benefit. Classify-
ing NHLs based on cell-of-origin subtypes or presence 
of other molecular features portends important biologi-
cal, prognostic and therapeutic implications. Agents tar-
geting the oncogenic drivers of DLBCL subsets might 
expand the number of DLBCL patients achieving a cure, 
and are in various stages of investigation, as reviewed 
elsewhere [15, 28].
Molecular similarities between DLBCL and FL have 
provided insight into the potential of both NHL subtypes 
to respond to agents targeting common genetic altera-
tions [86]. Despite differences in clinical behaviour, FL, 
similar to GCB-DLBCL, develops from GC B cells. Mark-
ers of prognostic significance may be relevant to both 
DLBCL and FL management [86].
Whole genome/exome sequencing has also been 
instrumental in disclosing the genetic landscape of CLL, 
revealing mutations of cancer-related genes and events 
involved in disease initiation and progression. BCR sig-
nalling is an attractive molecular target in patients with 
CLL, with the BTK inhibitor ibrutinib showing clinical 
activity [36, 47].
Concluding remarks
The landscape of genomic and epigenomic changes 
associated with tumor transformation is increasingly 
disclosed due to the availability of new sequencing tech-
nologies and bioinformatic tools. Our appreciation of 
the heterogeneity of lymphoid tumors has grown fol-
lowing the use of high-throughput approaches. The 
unprecedented possibilities offered by these technolo-
gies will allow researchers and clinicians to develop novel 
and more effective treatment approaches. As the path 
towards integrative medicine and personalized treat-
ments progresses, knowledge sharing through infor-
matics databases will accelerate the dissemination and 
validation of experimental findings.
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